Although the p53 tumor-suppressor pathway is altered at the frequency of 87% in glioblastoma [57], previously, the TP53 status has not been associated with patient survival outcomes despite the well-established association of TP53 alteration with IDH mutations in glioma [23,24,58,59]. This evidence concerns the gene IDH1 and central nervous system cancer.